ACAD
30.96
-0.26
-0.83%
AEMD
0.24
-0.01
-5.07%
APRI
1.44
+0.11
+8.03%
ARNA
4.54
-0.02
-0.44%
ATEC
1.28
-0.02
-1.42%
CFN
59.52
-0.04
-0.07%
CNAT
5.92
+0.13
+2.19%
CRXM
0.21
0.00
-1.90%
CYTX
0.48
0.00
-0.85%
DXCM
60.52
-0.07
-0.12%
GNMK
13.3
+0.19
+1.45%
HALO
14.44
+0.29
+2.05%
ILMN
200.1
+2.24
+1.13%
INNV
0.21
+0.01
+2.50%
INO
8.41
-0.09
-1.06%
ISCO
0.06
+0.00
+4.35%
ISIS
69.71
+1.13
+1.65%
LGND
57.32
-0.1
-0.17%
LPTN
2.85
-0.04
-1.38%
MBVX
1.05
-0.1
-8.70%
MEIP
3.84
+0.12
+3.23%
MNOV
3.77
-0.02
-0.53%
MRTX
20.84
+0.38
+1.86%
MSTX
0.44
-0.01
-2.31%
NBIX
33.86
+0.47
+1.41%
NUVA
46.99
+0.52
+1.12%
ONCS
0.36
-0.02
-6.23%
ONVO
6.51
+0.02
+0.31%
OREX
5.34
-0.15
-2.73%
OTIC
31.64
-0.09
-0.28%
QDEL
24.27
-0.09
-0.37%
RCPT
111.05
-2.02
-1.79%
RGLS
18.35
+0.69
+3.92%
RMD
63.1
-0.22
-0.35%
SCIE
0.01
0.00
-9.60%
SPHS
0.46
+0.02
+3.86%
SRNE
10.67
+0.28
+2.69%
TROV
5.91
+0.06
+0.96%
VICL
1.02
-0.01
-0.82%
VOLC
17.97
+0.01
+0.03%
ZGNX
1.37
-0.01
-0.80%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Washington Monthly Ranks UC San Diego Nation’s Best University for Fifth Consecutive Year

August 25, 2014 – 8:50 am | Edit Post
Washington Monthly Ranks UC San Diego Nation’s Best University for Fifth Consecutive Year

In Washington Monthly’s annual college rankings measuring universities’ contributions to the public good, the University of California, San Diego has been rated the No. 1 college in the nation for the fifth consecutive year. The rankings are based on three categories: social mobility (recruiting and graduating low-income students), research (producing cutting-edge scholarship and Ph.D.,) and service (encouraging students to give back to their country). “It is a great honor to be recognized once again by Washington Monthly as the top college in the nation for contributing to the public good,” said Chancellor Pradeep K. Khosla. “This is an extraordinary achievement, as the criteria for this ranking exemplify our core values and our vision to be a student-centered, research-focused, service-oriented public university that provides opportunity for all.”

Washington Monthly Ranks UC San Diego Nation’s Best University for Fifth Consecutive Year

August 25, 2014 – 8:50 am | Edit Post
Washington Monthly Ranks UC San Diego Nation’s Best University for Fifth Consecutive Year

In Washington Monthly’s annual college rankings measuring universities’ contributions to the public good, the University of California, San Diego has been rated the No. 1 college in the nation for the fifth consecutive year. The rankings are based on three categories: social mobility (recruiting and graduating low-income students), research (producing cutting-edge scholarship and Ph.D.,) and service (encouraging students to give back to their country). “It is a great honor to be recognized once again by Washington Monthly as the top college in the nation for contributing to the public good,” said Chancellor Pradeep K. Khosla. “This is an extraordinary achievement, as the criteria for this ranking exemplify our core values and our vision to be a student-centered, research-focused, service-oriented public university that provides opportunity for all.”

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

In honor of the Monday morning blues, here is a sleepy Celsius quiz

August 25, 2014 – 6:04 am | Edit Post

Get Started!

In honor of the Monday morning blues, here is a sleepy Celsius quiz

August 25, 2014 – 6:04 am | Edit Post

Get Started!

BioKier Takes a Shot at a New Kind of Diabetes Drug

August 25, 2014 – 4:00 am | Edit Post
BioKier Takes a Shot at a New Kind of Diabetes Drug

Diabetics know all too well that needle sticks are a routine part of managing their disease. Insulin injections have been part of the diabetes standard of care for decades. And in recent years, a new…

[[Click headline to continue reading.]]

BioKier Takes a Shot at a New Kind of Diabetes Drug

August 25, 2014 – 4:00 am | Edit Post
BioKier Takes a Shot at a New Kind of Diabetes Drug

Diabetics know all too well that needle sticks are a routine part of managing their disease. Insulin injections have been part of the diabetes standard of care for decades. And in recent years, a new…

[[Click headline to continue reading.]]